drugset / Trial / NCT05346874

Neoadjuvant TACiE in Locally Advanced Gastric Cancer

NCT05346874 ↗

Phase 2 Unknown 37 enrolled Shanghai Zhongshan Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-center, single-arm, phase 2 trial to evaluate the feasibility and safety of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and gastroesophageal junction. The TACiE protocol includes four cycles. Transcatheter oxaliplatin and concurrent embolism on day 1 and oral S-1 on day 1-14 will be administrated in the first and third cycles. Intra-venous oxaliplatin on day 1 and oral S-1 on day 1-14 (SOX) will be administrated in the second and fourth cycles.

Timeline

Start
2022-06-01
Primary completion
2023-06-01
Completion
2025-05-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 85 mg/m2 Other
Subject Oxaliplatin Small molecule 135 mg/m2 Other
Subject Teysuno Small molecule 40 mg Oral
Subject Teysuno Small molecule 60 mg Oral

Indications